missing translation for 'onlineSavingsMsg'
Få mere at vide
  1. Home
  2. Products
  3. Proteinanalysereagenser
  4. Bioaktive små molekyler
  5. 18787446

Tocris Bioscience™ RAGE 229
GREENER_CHOICE

Artikelnummer. 18787446
Skift visning
Klik for at se tilgængelige muligheder
Mængde:
5 mg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Artikelnummer. Mængde
18787446 5 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Denne vare kan ikke returneres. Se returpolicy
Artikelnummer. 18787446 Leverandør Tocris Bioscience™ Leverandørnr. 7701/5

Please to purchase this item. Need a web account? Register with us today!

Denne vare kan ikke returneres. Se returpolicy

Beskrivelse

ctRAGE-DIAPH1 interaction antagonist; reduces inflammatory signaling in diabetic mice

RAGE 229 is an antagonist of the interaction between the cytoplasmic tail of the receptor for advanced glycation end products (ctRAGE) and the formin, Diaphanous-1 (DIAPH1) (KD for binding to ctRAGE = 2 nM). RAGE 229 inhibits the migration of human aortic smooth muscle cells in an in vitro wound healing assay (IC50 = 120 nM). RAGE 229 reduces short- and long-term complications of diabetes in mouse models, without lowering blood glucose concentrations. RAGE 229 also reduces plasma concentrations of TNF-α, IL-6, and CCL2/JE-MCP1 and attenuates inflammatory signaling in diabetic mice.
TRUSTED_SUSTAINABILITY

Tekniske data

Kemisk navn eller materiale N-[4-[7-Cyano-4-(4-morpholinylmethyl)-2-quinolinyl]phenyl]acetamide
CAS 2143072-85-7
Mængde 5 mg
Mål AGER
Molekylær formel C23H22N4O2
Renhed 0.98
Produkttitel
Vælg et problem

Ved at klikke på Send, anerkender du, at du kan blive kontaktet af Fisher Scientific med hensyn til den feedback, du har givet i denne formular. Vi deler ikke dine oplysninger til andre formål. Alle angivne kontaktoplysninger skal også vedligeholdes i overensstemmelse med vores Privatlivspolitik.